Cost of Revenue Comparison: Perrigo Company plc vs Xencor, Inc.

Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost structures is crucial. Perrigo Company plc, a global consumer self-care company, and Xencor, Inc., a biopharmaceutical firm, present a fascinating study in contrasts. From 2014 to 2023, Perrigo's cost of revenue consistently dwarfed that of Xencor, averaging nearly 36 times higher. Perrigo's costs peaked in 2020, reaching a staggering 3.25 billion, while Xencor's highest was in 2023 at 254 million. This disparity highlights the scale and operational differences between a consumer-focused giant and a specialized biotech innovator. Interestingly, both companies experienced fluctuations, with Perrigo's costs decreasing by 8% from 2020 to 2021, while Xencor saw a dramatic 97% drop in 2021, only to rebound in 2023. These trends underscore the dynamic nature of cost management in these industries.